Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Predix expands deal with CFFT
September 2006
SHARING OPTIONS:

LEXINGTON, Mass—Predix Pharmaceuticals will expand its research, development and commercialization agreement with Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the non­profit drug discovery and develop­ment affiliate of the Cystic Fibrosis Foundation.
 
Predix has already achieved another milestone under the origi­nal agreement and will receive the associated $1.5 million payment. Under the amended agreement, Predix may be eligible for up to an additional $3.5 million in research funding and milestone payments, bringing the total value of its CFFT collaboration to $16 million.
 
"We are very pleased that we are now at the point where Predix can begin conducting drug discovery research based on its innovative computer model of the cystic fibro­sis protein CFTR," says Dr. Robert J. Beall, president and CEO of the Cystic Fibrosis Foundation. "[We] are hopeful that the Predix team will identify compounds that could become new potential therapies for people with cystic fibrosis."
 
The first research program under this agreement utilizes Predix's proprietary PREDICT technology to characterize the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel protein. Through this technology, Predix has modeled several domains of the structure of this protein and the resulting model has been validated. The original agreement between Predix and CFFT has been expanded to allow for additional research by Predix, including the initiation of screening efforts against certain regions of the CFTR protein to help restore proper functioning of this ion channel.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.